The role of fulvestrant in endometrial cancer

References

• Krasner C. Aromatase inhibitors in gynaecologic cancer. J Steroid Biochem Mol Biol. 2007 Aug–Sep;106(1–5):76–80.
   PubMed Web of Science ®Google Scholar
• Colombo N, Preti E, Landoni F, et al. Endometrial cancer ESMO clinical practice guide lines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24(Suppl 6):vi33–vi8.
   PubMed Web of Science ®Google Scholar
• Hetch JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 2006 Oct 10;24(29):4783–4791.
   PubMed Web of Science ®Google Scholar
• Humber CE, Tierney JF, Symonds RP, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol. 2007;18(3):409–420.
   PubMed Web of Science ®Google Scholar
• Temkin SM, Fleming G. Current treatment of metastatic endometrial cancer. Cancer Control. 2009 Jan;16(1):38–45.
   PubMed Web of Science ®Google Scholar
• Oehler MK, Fung A, Jobling TW. Advances in the treatment of endometrial cancer. J Br Menopause Soc. 2005 Mar;11(1):18–22.
   PubMedGoogle Scholar
• Kokka F, Brockbank E, Oram D, et al. Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Databse Syst Rev. 2010 Dec 8;(12):CD007926. DOI:10.1002/14651858.CD007926.pub2
   Google Scholar
• Boisen MM, Andersen CL, Sreekumar S, et al. Treating gynaecologic malignancies with selective estrogen receptor downregulators (SERDs): promise and challenges. Mol Cell Endocrinol. 2015;418:322–333. .
   PubMed Web of Science ®Google Scholar
• Bogliolo S, Gardella B, Dominoni M, et al. Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma. Arch Gynecol Obstet. 2016 Apr;293(4):701–708.
   PubMed Web of Science ®Google Scholar
• Osborne CK, Wakeling A, Nicholson RI. Fulvestrant: an estrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 2004;90(Suppl.1):S2–S6.
   PubMed Web of Science ®Google Scholar
• Bross PF, Cohen MH, Williams GA, et al. FDA drug approval summaries: fulvestrant. Oncologist. 2002;7(6):477–480.
   PubMed Web of Science ®Google Scholar
• Turner NC, Ro J, André F, et al. PALOMA3 Study Group; Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015 Jul 16;373(3):209–219. Epub 2015 Jun 1. DOI:10.1056/NEJMoa1505270
   PubMed Web of Science ®Google Scholar
• Wittmann BM, Sherk A, McDonnel DP. Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators. Cancer Res. 2007 Oct 1;67(19):9549–9560.
   PubMed Web of Science ®Google Scholar
• Buzdar AU, Robertson JF. Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer. Ann Pharmacother. 2006;40:1572–1583.
   PubMed Web of Science ®Google Scholar
• Bross PF, Baird A, Chen G, et al. Fulvestrant in postmenopausal women with advanced breast cancer. Clin Cancer Res. 2003 Oct 1;9(12):4309–4317.
   PubMed Web of Science ®Google Scholar
• McClelland RA, Manning DL, Gee JM, et al. Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes. Breast Cancer Res Treat. 1996;41(1):31–41.
   PubMed Web of Science ®Google Scholar
• Hu XF, Veroni M, De Luise M, et al. Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780. Int J Cancer. 1993 Nov 11;55(5):873–876.
   PubMed Web of Science ®Google Scholar
• Lieberman ME, Gorski J, Jordan VC. An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro. J Biol Chem. 1983 Apr 25;258(8):4741–4745.
   PubMed Web of Science ®Google Scholar
• Murphy CS, Jordan VC. Structural components necessary for the antiestrogenic activity of tamoxifen. J Steroid Biochem. 1989;34(1–6):407–411.
   PubMedGoogle Scholar
• Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Res. 1990 Jul 15;50(14):4177–4189.
   PubMed Web of Science ®Google Scholar
• Wakeling AE, Bowler J. Steroidal pure antiestrogens. J Endocrinol. 1987 Mar;112(3):R7–R10.
   PubMed Web of Science ®Google Scholar
• Robinson SP, Jordan VC. The paracrine stimulation of MCF-7 cells by MDA-MB-231 cells: possible role in antiestrogen failure. Eur J Cancer Clin Oncol. 1989 Mar;25(3):493–497.
   PubMedGoogle Scholar
• Dennis AP, Haq RU, Nawaz Z. Importance of the regulation of nuclear receptor degradation. Front Biosci. 2001 Aug; A.J. Virtual Libr 6:D954–D959.
   PubMed Web of Science ®Google Scholar
• Nawaz Z, Lonard DM, Dennis AP, et al. Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA. 1999 Mar 2;96(5):1858–1862.
   PubMed Web of Science ®Google Scholar
• Scheffner M, Huibregtse JM, Vierstra RD, et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 1993 Nov 5;75(3):485–505.
   Web of Science ®Google Scholar
• Kamitani T, Kito K, Nguyen HP, et al. Characterization of NEDD8, a developmentally down-regulated ubiquitin-like protein. J Biol Chem. 1997 Nov 7;272(45):28557–28562.
   PubMed Web of Science ®Google Scholar
• Eakin CM, MacCoss MJ, Finney GL, et al. Estrogen receptor α is a putative substrate for the BRCA1 ubiquitin ligase. Proc Natl Acad Sci. 2007 Apr 3;104(14):5794–5799.
   PubMed Web of Science ®Google Scholar
• Duong V, Boulle N, Daujat S, et al. differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents. Cancer Res. 2007 Jun 1;67(11):5513–5521.
   PubMed Web of Science ®Google Scholar
• Sun J, Zhou W, Kaliappan K, et al. ERalpha phosphorylation at Y537 by Src triggers E6-AP-ERalpha binding, ERalpha ubiquitylation, promoter occupancy, and target gene expression. Mol Endocrinol. 2012 Sep;26(9):1567–1577.
   PubMed Web of Science ®Google Scholar
• Zhang QG, Han D, Wang RM, et al. C terminus of Hsc70-interacting protein (CHIP)-mediated degradation of hippocampal estrogen receptor-alpha and the critical period hypothesis of estrogen neuroprotection. Proc Natl Acad Sci USA. 2011 Aug 30;108(35):E617–E624.
   PubMed Web of Science ®Google Scholar
• Alarid ET, Bakopoulos N, Solodin N. Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down regulation. Mol Endocrinol. 1999 Sep;13(9):1522–1534.
   PubMed Web of Science ®Google Scholar
• Wijayaratne AL, McDonnell DP. The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulator. J Biol Chem. 2001 Sep 21;276(38):35684–35692.
   PubMed Web of Science ®Google Scholar
• Fan M, Bigsby RM, Nephew KP. The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)- a and essential for the antiproliferative activity of IC182,780 in ERa-positive breast cancer cells. Mol Endocrinol. 2003 Mar;17(3):356–365.
   PubMed Web of Science ®Google Scholar
• Stanisic V, Malovannaya A, Quin J, et al. OTU domani-containing ubiquitinates estrogenreceptor (ER) alpha and affects ERalpha transcriptional activity. J Biol Chem. 2009 Jun 12;284(24):16135–16145.
   PubMed Web of Science ®Google Scholar
• Pfoh R, Lacdao IK, Saridakis V. Deubiquitinates and the new therapeutic opportunities offered to cancer. Endocr Relat Cancer. 2015 Feb;22(1):T35–T54.
   PubMed Web of Science ®Google Scholar
• Long X, Nephew KP. Fulvestrant (IC 182780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha. J Biol Chem. 2006 Apr 7;281(14):9607–9615.
   PubMed Web of Science ®Google Scholar
• Marsaud VR, Gougelet AL, Maillard S, et al. Various phosphorylation pathways, depending on agonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cell. Mol Endocrinol. 2003 Oct;17(10):2013–2027.
   PubMed Web of Science ®Google Scholar
• Estimation Program Interface (EPI) suite. Ver.3.12; US EPA; 2004 Nov 30 [cited 2008 Oct 8]. Available from: http://www.epa.gov/oppt/exposure/pubs/episuitedl.htm
   Google Scholar
• Thomson Health Care Inc. Physicians’ desk reference. 62 ed. Montvale (NJ); 2008. p. 663.
   Google Scholar
• DrugBank. Fulvestrant; [cited 2016 May 20]. Available from: http://www.drugbank.ca/drugs/DB00947
   Google Scholar
• Howell A, DeFriend DJ, Robertson JF, et al. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-estrogen ICI 182780 in women with advanced breast cancer. Br J Cancer. 1996 Jul;74(2):300–308.
   PubMed Web of Science ®Google Scholar
• Robertson JFR, Harrison M. ICI 182,780 (‘Faslodex’) (FAS) 250 mg monthly intramuscular (i.m.) injection shows consistent PK during long-term dosing in postmenopausal (PM) women with advanced breast cancer (ABC). Proc Am Assoc Cancer Res. 2001;42:856. abstract 4591.
   Google Scholar
• Robertson JFR, Harrison M. Fulvestrant: pharmacokinetics and pharmacology. Br J Cancer. 2004 Mar;90(Suppl 1):S7–S10.
   PubMed Web of Science ®Google Scholar
• Harrison M, Laight A, Clarke DA, et al. Pharmacokinetics and metabolism of fulvestrant after oral, intravenous and intramuscular administration in healthy volunteers. Proc ASCO. 2003;22:45. abstract 311.
   Google Scholar
• Robertson JFR, Erikstein B, Osborne CK, et al. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer. Clin Pharmacokinet. 2004;43(8):529–538.
   PubMed Web of Science ®Google Scholar
• American Society of Health System Pharmacists. AHFS drug information 2008. Maryland: Bethesda; 2008. p. 1074.
   Google Scholar
• US Natl Inst Health. DailyMed. Current Medication Information for Faslodex (Fulvestrant); 2006 June [cited 2008 Nov 13]. Available from: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=1615
   Google Scholar
• Laight A, Yates RA, Rose A, et al. Fulvestrant is unlikely to be involved in clinically significant drug interactions – results of clinical trials in healthy male volunteers. Proc ASCO. 2003;22:33. abstract 133.
   Google Scholar
• Suga S, Kato K, Ohgami T, et al. An inhibitory effect on cell proliferation by blockage of the MAPK/estrogen receptor/MDM2 signal pathway in gynecologic cancer. Gynecol Oncol. 2007 May;105(2):341–350.
   PubMed Web of Science ®Google Scholar
• O’Regan RM, Cisneros A, England GM, et al. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst. 1998;90:1552–1558.
   PubMed Web of Science ®Google Scholar
• Farnell YZ, Ing NH. The effects of estradiol and selective estrogen receptor modulators on gene expression and messenger RNA stability in immortalized sheep endometrial stromal cells and human endometrial adenocarcinoma cells. J Steroid Biochem Mol Biol. 2003 Mar;84(4):453–461.
   PubMed Web of Science ®Google Scholar
• Boehme K, Simon S, Mueller SO. Gene expression profiling in Ishikawa cells: a fingerprint for estrogen active compounds. Toxicol Appl Pharmacol. 2009 Apr1;236(1):85–96.
   PubMed Web of Science ®Google Scholar
• Block M, Fister S, Emons G, et al. Antiproliferative effects of antiestrogens and inhibitors of growth factor receptor signaling on endometrial cancer cells. Anticancer Res. 2010 Jun;30(6):2025–2031.
   PubMed Web of Science ®Google Scholar
• Petrie WK, Dennis MK, Hu C, et al. G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growth. Obstet Gynecol Int. 2013;2013:472720.
   PubMedGoogle Scholar
• Addo S, Yates RA, Laight A. A phase I trial to assess the pharmacology of the new estrogen receptor antagonist fulvestrant on the endometrium in healthy post-menopausal volunteers. Br J Cancer. 2002 Dec 2; 87(12):1354–1359. .
   PubMed Web of Science ®Google Scholar
• Covens AI, Filiaci V, Gersell D, et al. Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2011 Feb;120(2):185–188. .
   PubMed Web of Science ®Google Scholar
• Emons G, Gunthert A, Thiel FC, et al. Phase II study of fulvestrant 250 mg/month in patients with recurrent of metastatic endometrial cancer: a study of tha Arbeitsgemeinschatt Gynakologische Onkologie. Gynecol Oncol. 2013 Jun;129(3):495–499. .
   PubMed Web of Science ®Google Scholar
• Croxtall JD, McKeage K. Fulvestrant: a review of its use in the management of hormone-receptor positive metastatic breast cancer in postmenopausal women. Drugs. 2011 Feb 12;71(3):363–380.
   PubMed Web of Science ®Google Scholar
• Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010 Oct 20;28(30):4594–4600.
   PubMed Web of Science ®Google Scholar
• Health NIo. A study of ARN-810 (GDC-0810) in post-menopausal women with locally advanced or metastatic estrogen receptor positive breast cancer; [cited 2016 May 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT01823835
   Google Scholar
• Wardell SE, Marks JR, McDonnell DP. The turnover of estrogen receptor a by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. Biochem Pharmacol. 2011 Jul 15;82(2):122–130.
   PubMed Web of Science ®Google Scholar
• Calligé M, Kieffer I, Richard-Foy H. CSN5/Jab1 is involved in ligand-dependent degradation of estrogen receptor {alpha} by the proteasome. Mol Cell Biol. 2005 Jun;25(11):4349–4358.
   PubMed Web of Science ®Google Scholar
• Slomovitz BM, Jiang Y. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015;33:930–936.
   PubMed Web of Science ®Google Scholar
• Mani S, Herceg Z. DNA demethylating agents and epigenetic therapy of cancer. Adv Genet. 2010;70:327–340.
   PubMed Web of Science ®Google Scholar
• Raha P, Thomas S, Thurn KT, et al. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Breast Cancer Res. 2015 Feb 25;17:26.
   PubMed Web of Science ®Google Scholar